Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Shares Outstanding (Weighted Average) (2016 - 2025)

Lisata Therapeutics' Shares Outstanding (Weighted Average) history spans 13 years, with the latest figure at $8.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 4.3% year-over-year to $8.7 million; the TTM value through Dec 2025 reached $8.7 million, up 4.3%, while the annual FY2025 figure was $8.7 million, 4.3% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $8.7 million in Q4 2025 per LSTA's latest filing, roughly flat from $8.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $8.7 million in Q4 2025 to a low of $8.0 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $8.3 million, with a median of $8.3 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 3.17% in 2024, then increased 4.3% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $8.1 million in 2023, then rose by 3.17% to $8.3 million in 2024, then rose by 4.3% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Shares Outstanding (Weighted Average) are $8.7 million (Q4 2025), $8.6 million (Q3 2025), and $8.6 million (Q2 2025).